Novosti
|
This journal is indexed in Scopus |
|---|
Year 2012 Vol. 20 No 4
ONCOLOGY
A.V. HIDRANOVICH
BREAST CANCER OUTCOME PROGNOSIS BASED ON BLOOD SERUM BIOCHEMICAL INDICES
EE “Vitebsk State Medical University”
The Republic of Belarus
Objectives. To evaluate the prognostic significance of the serum biochemical indices in patients with breast cancer.
Methods. To design the model 162 patients suffering from the breast cancer have been examined, 12 of them with the cured breast cancer for more than 5 years were under the dispensary supervision; 9 females with benign hyperplastic breast diseases and 18 healthy women of corresponding age. The results of the 5-year survival prognosis were verified in the group consisting of 44 patients.
Results. To refer the patient to one of the prognostic groups one suggests to use the interpretation of the mathematics analysis of the complex of the blood serum biochemical indices, including autocrine motility factor (AMF), concentration of high density lipoproteins cholesterol (HDL CHOL), relative concentration of arachidonic acid (C20:4), stearic acid (C18:0), concentration of general serum cholesterol (CHOL). For prognosis two discriminant functions (DF1 and DF2) were calculated with further reference of a patient to one of the risk groups. 5-year survival prognosis after diagnosis has been made for the patients of the 1st risk group composes 79,8±5,5%, for the patients of the 2 risk group – 50,8±7,4%, for the patients of the 3 risk group – 10,4±5,6%.
A simplified method includes stratification of risk of hematogenic metastasis based on interpretation of AMF activity.
Conclusions. The performed research let to propose a new method for prognosis of breast cancer outcome and to reveal heterogeneity in clinically homogenous groups as well as to suggest the method to prognosticate the breast cancer outcome.
1. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology. 2011 Aug;22(8):1736–47.
2. Page DL. Prognosis and breast cancer. Recognition of lethal and favourable prognostic types. Am J Surg Pathol. 1991;15:334–49.
3. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol. 1989;7:1239–51.
4. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011;103(22):1656–64.
5. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 Nov;19(5):403–10.
6. De Mascarel I, Bonichon F, Durand M, Mauriac L, MacGrogan G, Soubeyran I, Picot V, Avril A, Coindre JM, Trojani M. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer. 1998 Jan;34(1):58–65.
7. Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Kruger A, Kiechle M, Janicke F, Schmitt M, Foekens JA. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 2002 Aug 15;62(16):4617–22.
8. Page DL. Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am J Surg Pathol. 1991 Apr;15(4):334–49.
9. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. Clin Oncol. 2001 Apr 15;19(8):2334–56.
10. Van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002 Dec 19;347(25):1999–2009.
11. Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol. 2003 Sep 15;21(18):3469–78.
12. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008 May;13(5):477–93.
13. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9(6):606–16.
14. Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH, Lee KS. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol. 2008;19(4):675–81.
15. Keyhani M. Nasizadeh S, Dehghannejad A. Serum Ca15-3 Measurement In Breast Cancer Patients Before And After Mastectomy. Arch Iranian Med. 2005; 8(4):263–66.
16. Catanzaro PJ. Evolution of sub-clinical metastases in breast cancer. J Clin Oncol. 2008;26(May 20 Suppl; abstr 12024).
17. Ahmad A, Aboukameel A, Kong D, Wang Z, Sethi S, Chen W, Sarkar FH, Raz A. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res. 2011 May 1;71(9):3400–409.
210023, Respublika Belarus, Vitebsk, pr. Frunze, d. 27, UO «Vitebskiy gosudarstvennyiy meditsinskiy universitet», kafedra onkologii s kursami luchevoy diagnostiki, terapii, FPK i PK,
e-mail: hidranovich@mail.ru,
Gidranovich Anton Viktorovich
Gidranovich A.V., Assistant of the Oncology Chair with the Course of Radial Diagnostics, Therapy, Faculty of Training and Retraining of the Staff of EE “Vitebsk State Medical University”. The Republic of Belarus.
Article in the .pdf format
